University of Manchester
Latest From University of Manchester
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced April through May 2016.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced March through April 2016.
Spectromics Ltd. was formed to license and commercialize technology that can detect bacterial susceptibility to drugs in only 10 minutes by detecting the underlying metabolism of pathogens. The start-up aims to incorporate it into a POC test that doctors can use to expose a patient's urine sample to eight different antibiotics, to see which can kill the bugs and which meet resistance.
Blueberry Therapeutics Ltd. plans to exploit nanopolymer drug delivery technologies to create safer and more effective therapeutics to treat inflammation and infection. It will start by targeting OTC indications using nanotechnology and off-patent drugs, as this will enable its candidates to move toward the market more quickly and generate revenue.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.